Patent approval now also secured in the US, the largest IPF market
Following the recent patent application approvals in Japan and China, the patent (composition of matter) for OXC-201, Oxcias potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), has now also been approved in the largest market, the US. The US represents 57% of the prevalence and incidence of IPF in the 7 major markets and as much as 82% of the market value. The patent is valid at least until 2040.
Additional national and regional patent applications are pending in Europe (EPO - European Patent Organization) and Canada.
As previously communicated, the EIC (European Innovation Council) awarded Oxcia AB in early 2023 a grant of 2.5 million euros within the EIC-Transition program for the next phase of the development of OXC-201.
About OXC-201
OXC-201 is a small molecule inhibitor of OGG1. By targeting the DNA repair enzyme OGG1 (8-oxo guanine DNA glycosylase-1), OXC-201 inhibits binding of OGG1 to DNA and thereby the modulation of gene transcription. OGG1 plays a significant role in modulating inflammation and fibrogenesis; genetic downregulation or chemical inhibition of OGG1 has been shown to protect against inflammation and fibrosis in several experimental disease models.
For more information, please contact:
Christina Kalderén, Pre-clinical Director
Email: christina.kalderen@oxcia.com
Or:
Ulrika Warpman Berglund, CEO
Email: ulrika.warpmanberglund@oxcia.com
Briefly about Oxcia
Oxcia AB conducts innovative research through its unique way of utilizing oxidative DNA damage and DNA Damage response(1) and develops novel, safe and effective treatments for patients suffering from cancer, inflammation or fibrosis. Oxcia currently has two drug candidates, both with first-in-class potential. OXC-101 is in early clinical development for the treatment of solid and hematological cancers. OXC-201 is being developed as a treatment for inflammation and fibrosis-related diseases and is in the preclinical phase.
More information about Oxcia is available at www.oxcia.com
(Note (1): DNA Damage Response, DDR – the body's processes to in various ways repair the damage that occurs to DNA)